Table 6 Dysregulation of CDK2 in clinical samples
From: A review on the role of cyclin dependent kinases in cancers
Tumor type | Samples | Expression (Tumor vs. Normal) | Kaplan–Meier analysis (impact of regulators dysregulation) | Multivariate Cox regression analysis | Association of dysregulation of regulators with clinicopathologic characteristics | References |
|---|---|---|---|---|---|---|
Acute myeloid leukemia | 44 patients with AML and 20 healthy controls | Up-regulation of TBK1 (which regulated CDK2) | _ | _ | [95] | |
27 patients with relapsed/refractory AML with anthracycline resistance TCGA database | Up-regulation of HDAC3-AKT-P21-CDK2 signaling | Shorter OS and EFS | _ | [101] | ||
Bladder cancer | GSE32894 TCGA dataset 40 patients | Up-regulation of MTHFD2 | Shorter OS | _ | grade and stage | [107] |
33 PTANCT | Down-regulation of miR-3619 (which regulated CDK2) Up-regulation of CDK2 | Shorter OS | miR-3619 and p21 expressions were found to be an independent risk factors for poor OS | tumor stage and grade | [105] | |
Breast cancer | 344 patients | Up-regulation of ACTL6A/MYC/CDK2 axis | Shorter OS and RFS | High levels of ACTL6A and T, N classification were found as independent prognostic factors for the 5-year OS in TNBC subtype. | _ | [110] |
METABRIC dataset | Up-regulation of CDK2 and CDK4 | Shorter OS | _ | _ | [111] | |
116 breast cancer tissues and 39 adjacent normal tissues 84 breast cancer patients | Up-regulation of RHBDD1 (which regulated CDK2) | _ | _ | pathological tumor (pT) stage, pathological TNM stage and estrogen receptor (ER) expression | [114] | |
TCGA dataset | Up-regulation of CDK2 | _ | _ | _ | [122] | |
Cervical cancer | 108 patients and 54 normal controls | Up-regulation of Cyclin A and CDK2 | Shorter OS | _ | _ | [176] |
GEO database (GSE102686) 52 PTANCT | Up-regulation of hsa_circ_0000520 (which regulated CDK2) | _ | _ | _ | [128] | |
GSE102686 | Up-regulation of circ_0084927 (which regulated CDK2) | _ | _ | _ | [129] | |
GEO database (GSE102686) 30 PTANCT 10 advanced cervical cancer tissues, and 7 normal cervical tissues TCGA dataset: 306 cervical cancer tissues and 13 healthy cervical tissues | Up-regulation of circZFR | _ | _ | lymphatic metastasis | [130] | |
Cholangiocarcinoma | TCGA database | Up-regulation of CDK2/5/9 | _ | _ | _ | [132] |
Colorectal cancer | TCGA dataset 8 PTANCT | Down-regulation of NPTX1 (which regulated CDK2) | _ | _ | _ | [133] |
TCGA dataset | Up-regulation of MEX3A (which regulated CDK2) | _ | _ | _ | [135] | |
109 PTANCT 158 PTANCT TCGA and GSE9348, GSE21510, GSE23878 and GSE33113 datasets | Up-regulation of SLCO4A1-AS1 (which regulated CDK2) | Shorter OS and DFS | SLCO4A1-AS1 expression was found to be an independent risk factor | TNM stage | [137] | |
Gastric cancer | GEO database (GSE13911: 38 gastric cancer samples and 31 normal samples) | Up-regulation of LINC01021 (which regulated CDK2) | Shorter OS | _ | pathological stage, metastasis, differentiation level, and tumor size | [139] |
100 PTANCT | Up-regulation of PCBP2 (which regulated CDK2) Up-regulation of CDK2 | _ | _ | _ | [140] | |
Glioma | TCGA, GTEx, CGGA, CancerSEA, and TISCH databases | Up-regulation of CDK2 | Shorter OS | _ | Grade, endothelial cells, macrophage, and NK cells | [177] |
35 PTANCT | Up-regulation of LINC00958 (which regulated CDK2) | Shorter OS | _ | _ | [142] | |
113 PTANCT | Up-regulation of HSP90AA1-IT1 (which regulated CDK2) | _ | _ | pathological grades | [143] | |
Growth hormone adenomas | 46 GHPA patients | Up-regulation of cyclin E and Cdk2 | _ | _ | invasion | [178] |
Hepatocellular carcinoma | 75 PTANCT | Up-regulation of MINCR and CDK2 | Shorter OS | _ | tumor size, TNM stage, lymph node metastasis, and serum alpha-fetoprotein levels | [179] |
TCGA dataset TCGA dataset: 371 patients (including 50 PTANCT) from | Up-regulation of HNRNPU (which regulated transcription of CDK2) | Shorter OS | _ | advanced tumor stage | [145] | |
Hepatocellular carcinoma | TCGA dataset (351 tumor CC tissues, 50 normal tissues) | Up-regulation of MAPRE1 | Shorter OS,RFS, PFS, DSS | _ | _ | [147] |
TCGA and GEO databases (GSE6764, GSE29721, GSE45436 and GSE62232) 105 PTANCT | Up-regulation of OLA1 (which regulated CDK2) | Shorter OS and DFS | OLA1 was found to be an independent prognostic factor for OS and DFS | tumor size, PVTT, TNM stage and tumor differentiation degree | [148] | |
62 PTANCT | Down-regulation of TPT1-AS1 (which regulated CDK2) | _ | _ | clinical stages | [149] | |
GEPIA database 63 PTANCT | Up-regulation of LINC00630 (which regulated CDK2) | _ | _ | TNM stage and lymph node metastasis | [150] | |
Lung cancer | GEO and TCGA databases | Up-regulation of CDK2 | _ | _ | IC50 of 89 antitumor drugs | [180] |
50 PTANCT | Down-regulation of miR-597 | Shorter OS | _ | pathological stage | [154] | |
Ovarian cancer | 64 PTANCT | Up-regulation of PLAC2 and Cdk2 | Shorter OS | _ | _ | [165] |
4 PTANCT 20 PTANCT | Up-regulation of Cul4B (which regulated CDK2) | Shorter OS and RFS | Tumor grade, Cul4B expression were found to be independent risk factors of patient DFS but while tumor grade, FIGO stage and Cul4B expression were identified as independent risk factors of patient OS | FIGO stage | [166] | |
Prostate cancer | GEO datasets (GSE6605 and GSE6606) | Up-regulation of CDK2 | Shorter OS | _ | recurrence | [167] |
Renal cell carcinoma | 85 PTANCT TCGA dataset | Up-regulation of WTAP (which regulated CDK2) | Shorter OS | _ | tumor size and TNM stage | [68] |
15 PTANCT | Up-regulation of TSG101 (which regulated CDK2) | _ | _ | _ | [169] | |
Soft tissue leiomyosarcoma | TCGA dataset 31 STLMS cases with or 22 cases without relapse after primary therapy | Up-regulation of PLA2G10 (which regulated CDK2) | worse RFS | _ | _ | [170] |